Page last updated: 2024-09-02

fingolimod hydrochloride and Leukoencephalopathy, Progressive Multifocal

fingolimod hydrochloride has been researched along with Leukoencephalopathy, Progressive Multifocal in 40 studies

Research

Studies (40)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (2.50)	29.6817
2010's	32 (80.00)	24.3611
2020's	7 (17.50)	2.80

Authors

Authors	Studies
Bai, X; Beard, K; Chaudhary, D; Khalid, SH; Lisak, RP; Srivastava, S; Sriwastava, S; Wen, S	1
Afanasjeva, B; Afanasjevas, D; Baltusiene, A; Berger, JR; Gleizniene, R; Mickeviciene, D; Rastenyte, D	1
Yukitake, M	1
Barritt, AW; Berger, JR; Das, E; Dizdarevic, S; Fisniku, LK; Morley, N; Nicholas, R; Saha, R; Seymour, M; Vera, J; Vundavalli, S	1
Adams, O; Aktas, O; Albrecht, P; Gembruch, O; Gold, R; Hadisurya, J; Hartung, HP; Hellwig, K; Kraemer, M; Pilgram-Pastor, S; Schneider-Hohendorf, T; Schwab, N; Sinnecker, T; Wrede, K	1
Alcalá Vicente, C; Bastida Paz, G; Ladrón Abia, P; Martínez Delgado, S	1
Derfuss, T; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Lorscheider, J; Oechtering, J	1
Oel, D; Rigler-Hohenwarter, K; Topakian, R; Trenkler, J	1
Alcala-Vicente, C; Bosca-Blasco, I; Casanova-Estruch, B; Coret-Ferrer, F; Gascon-Gimenez, F; Navarre-Gimeno, A; Perez-Miralles, FC	1
Berger, JR; Cree, BA; Dong, VM; Greenberg, B; Hemmer, B; Merschhemke, M; Ward, BJ	2
Oshima, Y; Tanimoto, T; Tojo, A; Yuji, K	1
Du Pasquier, R; Lalive, PH; Roth, S	1
AlOrainy, IA; AlTahan, AM; AlTahan, H; Berger, T	1
Takahashi, K	1
Ayzenberg, I; Deguchi, K; Gold, R; Kamada, M; Kufukihara, K; Kume, K; Nakahara, J; Schneider, R; Takata, T; Tomaske, L	1
Louapre, C; Lubetzki, C; Maillart, E; Papeix, C	1
Montalban, X; Tur, C	1
Biotti, D; Brassat, D; Bucciarelli, F; Bucur, C; Clanet, M; Gaina, J; Martin-Blondel, G; Peaureaux, D; Pignolet, B	1
Bencsik, K; Karácsony, M; Vécsei, L	1
Brew, BJ; Calic, Z; Cappelen-Smith, C; Cuganesan, R; Hodgkinson, SJ; McDougall, A	1
Gielen, J; Laton, J; Nagels, G; Van Schependom, J	1
Hartung, HP; Olsson, T; Warnke, C	1
Andreadou, E; Evangelopoulos, DS; Evangelopoulos, ME; Kilidireas, C; Koutoulidis, V	1
Cano, CA; Dubey, D; Stüve, O	1
Goodman, AD; Gross, RA; Gyang, TV; Hamel, J; Samkoff, L	1
Annovazzi, PO; Baroncini, D; Colombo, B; Comi, G; Ghezzi, A; Martinelli, V; Minonzio, G; Moiola, L; Rodegher, M; Zaffaroni, M	1
du Pasquier, R; Durand-Dubief, F; Marignier, R; Vukusic, S	1
Alves-Leon, SV; Becker, J; Brooks, JB; Correa, EC; Damasceno, A; Fragoso, YD; Gama, PD; Gama, RA; Maciel, EP; Matta, AP; Winckler, TC	1
Arru, G; Caocci, M; Dolei, A; Ibba, G; Leoni, S; Piu, C; Sechi, G; Serra, C; Uleri, E	1
Bargiela, D; Bianchi, MT; Chibnik, LB; De Jager, PL; Healy, BC; Westover, MB; Xia, Z	1
Tyor, WR; Vargas, DL	1
Bertrand, A; Boudot de la Motte, M; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Reach, P	1
Correale, J; Gaitán, MI	1
Yamamura, T	1
Bourdette, D; Yadav, V	1
Cervera, C	1
Bourdette, D; Gilden, D	1
Centonze, D; Gallo, P; Rinaldi, F; Rossi, S	1

Reviews

7 review(s) available for fingolimod hydrochloride and Leukoencephalopathy, Progressive Multifocal

Article	Year
Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. Journal of neurology, 2022, Volume: 269, Issue:3 Topics: Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors	2022
[Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics]. Brain and nerve = Shinkei kenkyu no shinpo, 2022, Volume: 74, Issue:10 Topics: Antiviral Agents; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab	2022
[[Natalizumab therapy, 2013]. Ideggyogyaszati szemle, 2014, Jul-30, Volume: 67, Issue:7-8 Topics: Adult; Antibodies, Monoclonal, Humanized; Disease Progression; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine	2014
Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Current opinion in neurology, 2016, Volume: 29, Issue:3 Topics: Alemtuzumab; Fingolimod Hydrochloride; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2016
Update on disease-modifying therapies for multiple sclerosis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:5 Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Infusions, Intravenous; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Polyomavirus Infections; Recurrence; Toluidines; Treatment Outcome; Tumor Virus Infections; United States; United States Food and Drug Administration	2017
[Molecular target drug development for curing multiple sclerosis]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:8 Topics: Abatacept; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmunity; Clinical Trials as Topic; Daclizumab; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunoconjugates; Immunoglobulin G; Integrin alpha4beta1; JC Virus; Leukoencephalopathy, Progressive Multifocal; Ligands; Lysophospholipids; Multiple Sclerosis; Natalizumab; Opportunistic Infections; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; Ustekinumab	2009
[Infections and fingolimod]. Revista de neurologia, 2012, Aug-16, Volume: 55, Issue:4 Topics: Community-Acquired Infections; Contraindications; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunocompromised Host; Immunologic Memory; Immunologic Surveillance; Immunosuppressive Agents; Kidney Transplantation; Leukoencephalopathy, Progressive Multifocal; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Opportunistic Infections; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Vaccination	2012

Other Studies

33 other study(ies) available for fingolimod hydrochloride and Leukoencephalopathy, Progressive Multifocal

Article	Year
Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report. BMC neurology, 2022, Aug-19, Volume: 22, Issue:1 Topics: Brain; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Natalizumab	2022
Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:2 Topics: Fingolimod Hydrochloride; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2023
Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC neurology, 2019, Aug-09, Volume: 19, Issue:1 Topics: Adult; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting	2019
Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis. Gastroenterologia y hepatologia, 2021, Volume: 44, Issue:2 Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Colitis, Ulcerative; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukapheresis; Leukoencephalopathy, Progressive Multifocal; Methylprednisolone; Middle Aged; Multiple Sclerosis; Remission Induction; Sphingosine-1-Phosphate Receptors; Tumor Necrosis Factor-alpha; Virus Activation	2021
Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Neurology(R) neuroimmunology & neuroinflammation, 2021, Volume: 8, Issue:1 Topics: Adjuvants, Immunologic; Antiviral Agents; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Interferon beta-1a; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines	2021
Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy? Neurology(R) neuroimmunology & neuroinflammation, 2021, Volume: 8, Issue:4 Topics: Adult; Cytomegalovirus Infections; Demyelinating Diseases; Encephalitis, Viral; Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Male; Sphingosine 1 Phosphate Receptor Modulators	2021
[Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice]. Revista de neurologia, 2017, May-16, Volume: 64, Issue:10 Topics: Adult; Contrast Media; Disability Evaluation; Disease-Free Survival; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroimaging; Oligoclonal Bands; Prospective Studies; Treatment Outcome; Young Adult	2017
Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2018, 05-15, Volume: 90, Issue:20 Topics: Aged; Brain; Disability Evaluation; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome	2018
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2019, Volume: 25, Issue:8 Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Rituximab	2019
Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 01-15, Volume: 92, Issue:3 Topics: Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2019
Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 01-15, Volume: 92, Issue:3 Topics: Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2019
Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis? The American journal of case reports, 2019, Jan-24, Volume: 20 Topics: Adult; Brain; DNA, Viral; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting	2019
Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2019, Volume: 63 Topics: Adult; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Sclerosis	2019
Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased? Neurology(R) neuroimmunology & neuroinflammation, 2019, Volume: 6, Issue:3 Topics: Europe; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Japan; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis	2019
Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 57, Issue:8 Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Propylene Glycols; Sphingosine	2013
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:4 Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine	2014
Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al. Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine	2014
Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases. Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:5 Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab	2015
Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:3 Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunoglobulins, Intravenous; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Retreatment; Treatment Outcome	2015
Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail. Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:3 Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Risk	2016
PML: The Dark Side of Immunotherapy in Multiple Sclerosis. Trends in pharmacological sciences, 2015, Volume: 36, Issue:12 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab	2015
Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod. The International journal of neuroscience, 2016, Volume: 126, Issue:12 Topics: Adrenal Cortex Hormones; Adult; Cohort Studies; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis; Natalizumab; Time Factors	2016
Fingolimod-associated PML in a patient with prior immunosuppression. Neurology, 2016, 05-10, Volume: 86, Issue:19 Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting	2016
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:10 Topics: Adolescent; Adult; Databases, Factual; Deprescriptions; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferons; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Treatment Failure; Treatment Outcome; Young Adult	2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. Annals of neurology, 2016, Volume: 80, Issue:5 Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Rituximab	2016
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis. Arquivos de neuro-psiquiatria, 2016, Volume: 74, Issue:8 Topics: Adult; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis; Natalizumab; Prospective Studies; Treatment Outcome; Viral Load	2016
JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab. Journal of neurovirology, 2017, Volume: 23, Issue:2 Topics: Adult; Antibodies, Viral; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroglia; Serine-Arginine Splicing Factors; Signal Transduction; Virus Activation	2017
Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology, 2017, Feb-14, Volume: 88, Issue:7 Topics: Adult; Clinical Decision-Making; Decision Support Techniques; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Randomized Controlled Trials as Topic; Risk; Time Factors; Treatment Outcome	2017
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse? Multiple sclerosis (Houndmills, Basingstoke, England), 2017, Volume: 23, Issue:4 Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome; White Matter	2017
Comment on extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse? Multiple sclerosis (Houndmills, Basingstoke, England), 2017, Volume: 23, Issue:4 Topics: Chronic Disease; Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Recurrence; White Matter	2017
New disease-modifying therapies and new challenges for MS. Current neurology and neuroscience reports, 2012, Volume: 12, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Propylene Glycols; Risk; Sphingosine	2012
Fingolimod and multiple sclerosis: four cautionary tales. Neurology, 2012, Nov-06, Volume: 79, Issue:19 Topics: Antibodies, Monoclonal, Humanized; Brain; Cerebrovascular Disorders; Encephalitis, Varicella Zoster; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis; Natalizumab; Nerve Fibers, Myelinated; Propylene Glycols; Sphingosine	2012
Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology, 2012, Nov-06, Volume: 79, Issue:19 Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Natalizumab; Propylene Glycols; Recurrence; Sphingosine	2012